title: Expedited partner therapy: a robust intervention.
abstract: BACKGROUND
  Expedited partner therapy (EPT) has been shown to reduce the risk of persistent or recurrent gonorrhea and chlamydial infection in heterosexuals, and to increase the proportion of sex partners receiving treatment. The objective of this analysis was to evaluate the consistency of EPT's effect across sociodemographic and behavioral subgroups.
  
  
  METHODS
  Subset analyses from a randomized controlled trial compared EPT to standard partner referral (SPR) in sociodemographic and behaviorally defined subgroups. Outcomes included persistent or recurrent infection in study participants and participants' report that their partners received treatment.
  
  
  RESULTS
  Reinfection risk was lower among EPT recipients than nonrecipients in 21 of 22 subgroups, with relative risks (RRs) varying from 0.4 to 0.94. Compared to persons receiving SPR, persons receiving EPT were more likely to report that their partners were very likely to have been treated in 33 of 34 subgroups (RRs range, 1.03-1.36). Although EPT reduced the risk of persistent or recurrent infection somewhat more in men (RR, 0.56; 95% CI, 0.3-1.08) than in women (RR, 0.81; 95% CI, 0.61-1.07) and more in persons with gonorrhea (RR, 0.32; 95% CI, 0.13-0.78) than those with chlamydial infection (RR, 0.82; 95% CI, 0.63-1.07), the RR of partners being treated associated with EPT was similar in men (RR, 1.21; 95% CI, 1.05-1.39) and women (RR, 1.18; 95% CI, 1.10-1.27), and also in persons with gonorrhea (RR, 1.33; 95% CI, 0.80-2.23) and chlamydial infection (RR, 1.33; 95% CI, 1.07-1.66).
  
  
  CONCLUSIONS
  In this study, EPT is shown to be superior to SPR across a wide spectrum of sociodemographic and behaviorally defined subgroups.
authors.affiliation: Department of Epidemiology and Public Health, University College Cork, Ireland. f.shiely@ucc.ie
authors.forename: Frances
authors.initials: F
authors.lastname: Shiely
authors.forename: Kevin
authors.initials: K
authors.lastname: Hayes
authors.forename: Katherine K
authors.initials: KK
authors.lastname: Thomas
authors.forename: Roxanne P
authors.initials: RP
authors.lastname: Kerani
authors.forename: James P
authors.initials: JP
authors.lastname: Hughes
authors.forename: William L H
authors.initials: WL
authors.lastname: Whittington
authors.forename: King K
authors.initials: KK
authors.lastname: Holmes
authors.forename: H Hunter
authors.initials: HH
authors.lastname: Handsfield
authors.forename: Matthew
authors.initials: M
authors.lastname: Hogben
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Golden
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002690:Chlamydia Infections / Q000188:drug therapy* / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006069:Gonorrhea / Q000188:drug therapy* / Q000517:prevention & control; D020010:Heterosexuality; D006801:Humans; D008297:Male; D012307:Risk Factors; D055502:Secondary Prevention; D012747:Sexual Partners; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents